Anavex Life Sciences Corp - Company Profile
Powered by 
All the sales intelligence you need on Anavex Life Sciences Corp in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Anavex Life Sciences Corp fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Anavex Life Sciences Corp.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Anavex Life Sciences Corp (Anavex) is a clinical-stage biopharmaceutical company that focuses on developing differentiated therapeutics for the treatment of neurodegenerative and other central nervous system (CNS) diseases, pain, and various types of cancer. The company’s target indications include Alzheimer’s disease, Parkinson’s disease, Rett syndrome, epilepsy, neuropathic pain, depression, prostate cancer, pancreatic cancer, infantile spasms, fragile X syndrome, Angelman syndrome, visceral pain, multiple sclerosis, depression, stroke, frontotemporal dementia, acute and neuropathic Pain and malignant melanoma. Its pipeline comprises one drug candidate and several compounds in diverse stages of pre-clinical study. Anavex's lead compound ANAVEX 2-73 is being developed for the treatment of Alzheimer’s disease, Parkinson’s disease and potentially other CNS diseases, including rare diseases. Anavex is headquartered in New York City, New York, the US.
Headquarters
United States of America
Address
630 5th Avenue, 20th Floor, New York City, 10111
Website
www.anavex.com
Telephone
1 800 6893939
No of Employees
34
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
AVXL (NASD)
EPS
XYZ
Net Income (2024)
XYZ
-7.8%
(2024 vs 2023)
Market Cap*
$250.2M
* As of and is in US$
Anavex Life Sciences Corp premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline: | Anavex |
| ANAVEX 2-73 (Blarcamesine): | |
| Alzheimer’s Disease | |
| XYZ | |
| XYZ | |
| XYZ |
Competitor Comparison
| Key Parameters | Anavex Life Sciences Corp | Johnson & Johnson | Merck & Co Inc | Novartis AG | GSK plc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | Switzerland | United Kingdom |
| City | New York City | New Brunswick | Rahway | Basel | London |
| State/Province | New York | New Jersey | New Jersey | Basel-Stadt | England |
| No. of Employees | 34 | 138,200 | 75,000 | 75,267 | 66,841 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Edward R Hammond | Chief Medical Officer | Senior Management | 2022 | - |
| Terrie Kellmeyer, PhD | Chief Executive Officer - Interim | Senior Management | 2026 | - |
| Sandra Boenisch | Treasurer; Principal Financial Officer | Senior Management | 2015 | - |
| Daniel Klamer | Vice President - Business Development and Scientific Strategy | Senior Management | - | - |
| Adebayo Laniyonu | Senior Vice President - Nonclinical Development | Senior Management | 2021 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer